Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

As part of the deal, Eli Lilly will acquire Scorpion's STX-478, an investigative once-daily oral medication being evaluated in a trial. Scorpion would spin out its non-phosphoinositide 3-kinase ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...

The UK-headquartered pharma is buying into a drug discovery platform developed by Boston, US biotech Scorpion Therapeutics, paying $75 million upfront to get the ball rolling on the partnership ...

The American pharmaceutical company Eli Lilly & Co. has entered into an agreement to acquire an experimental antitumor drug developed by Scorpion Therapeutics Inc. This is reported in a press release ...

In a significant move to bolster its pipeline and capabilities, Relay Therapeutics acquired Scorpion Therapeutics in early 2025 for $2.5 billion in cash. This acquisition is viewed by analysts as ...

AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target with small molecule drugs.

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

Additionally, the recent acquisition of Scorpion by Lilly for a significant ... Begin your TipRanks Premium journey today. Relay Therapeutics (RLAY) Company Description: Relay Therapeutics Inc ...

In a significant move to bolster its pipeline and capabilities, Relay Therapeutics acquired Scorpion Therapeutics in early 2025 for $2.5 billion in cash. This acquisition is viewed by analysts as a ...